Carsote M, Radoi V, Geleriu A, Mihai A, Ferechide D, Opris D, Paun D, Poiana C
"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania ; "C.I. Parhon" National Institute of Endocrinology, Bucharest, Romania.
"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
J Med Life. 2014;7 Spec No. 2(Spec Iss 2):49-53.
Lately, the in vitro and in vivo studies on serotonin metabolism have been pointing its influence in bone health. Also, there are no particular recommendations in performing the serum serotonin assessment in order to evaluate the skeletal status.
We aimed to correlate the bone turnover markers and lumbar bone mineral density (BMD) with serotonin.
There is a cross-sectional study in Caucasian postmenopausal women. They were not diagnosed with carcinoid syndrome, or bone anomalies, and received no treatment (including antiresorptives). The following bone formation markers were performed: serum alkaline phosphatase (AP), serum osteocalcin (OC), and the bone resorption marker: serum CrossLaps (CL). Serum serotonin (high-pressure liquid chromatography), as well as central DXA (GE Prodigy) were assessed.
191 women of 57.1 years mean age were grouped according to DXA (WHO criteria). The linear regression analysis between serum serotonin and CL were not statistically significant (SS), between serotonin and OC was SS in the newly diagnosed osteoporosis group (N=40, r=0.4, p=0.03), between serotonin and AP SS was found in osteopenia group (N=88, r=0.24, p=0.03), with no changes when adjusting for age and BMI. The partial correlation between serotonin and BMD was not SS.
The study raises the question of serotonin as a bone metabolism marker seeing that the results were not consistent. The main limit of our study was that we did not analyze the possible use of antidepressants to these women. Overall, this was a pilot study in clinical practice where few reports have been published, but still necessary, because the use of serum serotonin in current skeletal evaluation is still unclear.
最近，关于血清素代谢的体外和体内研究表明其对骨骼健康有影响。此外，在进行血清素评估以评估骨骼状态方面没有特别的建议。
我们旨在将骨转换标志物和腰椎骨密度（BMD）与血清素相关联。
对白人绝经后女性进行了一项横断面研究。她们未被诊断出患有类癌综合征或骨骼异常，且未接受任何治疗（包括抗吸收药物）。检测了以下骨形成标志物：血清碱性磷酸酶（AP）、血清骨钙素（OC），以及骨吸收标志物：血清交联C端肽（CL）。评估了血清素（高压液相色谱法）以及中心双能X线吸收法（GE Prodigy）。
根据双能X线吸收法（WHO标准）对191名平均年龄为57.1岁的女性进行分组。血清素与CL之间的线性回归分析无统计学意义（SS），在新诊断的骨质疏松症组（N = 40，r = 0.4，p = 0.03）中血清素与OC之间有统计学意义，在骨量减少组（N = 88，r = 0.24，p = 0.03）中血清素与AP之间有统计学意义，在调整年龄和体重指数后无变化。血清素与骨密度之间的偏相关性无统计学意义。
鉴于结果不一致，该研究提出了血清素作为骨代谢标志物的问题。我们研究的主要局限性在于我们没有分析这些女性使用抗抑郁药的可能性。总体而言，这是一项临床实践中的初步研究，此类报告发表较少，但仍然是必要的，因为目前血清素在骨骼评估中的应用仍不明确。
